Provided by Tiger Trade Technology Pte. Ltd.

Merck

119.37
+3.002.58%
Pre-market: 118.33-1.0400-0.87%08:17 EDT
Volume:10.22M
Turnover:1.22B
Market Cap:296.28B
PE:16.40
High:120.12
Open:117.30
Low:116.80
Close:116.37
52wk High:125.14
52wk Low:73.31
Shares:2.48B
Float Shares:2.48B
Volume Ratio:0.75
T/O Rate:0.41%
Dividend:3.24
Dividend Rate:2.71%
EPS(TTM):7.28
EPS(LYR):7.28
ROE:36.88%
ROA:12.04%
PB:5.63
PE(LYR):16.40

Loading ...

Health Rounds: Laser treatment before immunotherapy helps brain cancer patients live longer

Reuters
·
Mar 04

Merck’s Oncology Results And Tempus AI Deal Reframe Post Keytruda Future

Simply Wall St.
·
Mar 04

BRIEF-Tempus Announces Strategic Collaboration Agreement With Merck To Accelerate Ai-Driven Precision Medicine

Reuters
·
Mar 03

Tempus AI and Merck expand multi-year precision medicine collaboration

Reuters
·
Mar 03

Tempus Announces Strategic Collaboration Agreement With Merck to Accelerate AI-Driven Precision Medicine

THOMSON REUTERS
·
Mar 03

Tempus AI Inc -Co and Merck Announce Multi-Year Collaboration

THOMSON REUTERS
·
Mar 03

Analysts Have Conflicting Sentiments on These Healthcare Companies: Cogent Biosciences (COGT), Aquestive Therapeutics (AQST) and Merck & Company (MRK)

TIPRANKS
·
Mar 02

Leerink Partners Adjusts Price Target on Merck & Co to $129 From $128, Maintains Outperform Rating

MT Newswires Live
·
Mar 02

United Therapeutics' drug slows progression of rare lung condition in late-stage study

Reuters
·
Mar 02

Merck's Potential Renal Cancer Combos Show Significant Improvement in Meeting Primary Endpoints

MT Newswires Live
·
Mar 02

Merck's Pioneering HIF-2α Inhibitor Demonstrates Positive Outcomes in Two Phase III Trials

Stock News
·
Mar 02

Merck announces results from Phase 3 Litespark-022 trial

TIPRANKS
·
Mar 02

BRIEF-Merck & Co Inc Says FDA Sets PDUFA Date Of June 19, 2026 For Welireg And Keytruda

Reuters
·
Feb 28

Merck Reports Phase 3 LITESPARK-022 Win for Keytruda Plus Welireg in Adjuvant Kidney Cancer

Reuters
·
Feb 28

Merck & Co Inc - Keytruda Plus Welireg Reduces Risk of Recurrence or Death by 28%

THOMSON REUTERS
·
Feb 28

BRIEF-Merck Says Welireg Plus Lenvima Reduces Risk Of Disease Progression By 30%

Reuters
·
Feb 28

FDA accepts Merck and Eisai sNDAs for Welireg plus Lenvima in advanced RCC

Reuters
·
Feb 28

Merck says Welireg plus Lenvima cuts progression or death risk 30% in advanced RCC trial

Reuters
·
Feb 28

Welireg® (Belzutifan) Plus Lenvima® (Lenvatinib) Reduced the Risk of Disease Progression or Death by 30% Compared to Cabozantinib in Certain Previously Treated Patients With Advanced Renal Cell Carcinoma (Rcc)

THOMSON REUTERS
·
Feb 28

Merck & Co Inc - FDA Accepts Review of Two Supplemental Ndas for Welireg Plus Lenvima

THOMSON REUTERS
·
Feb 28